Ireland· IE-PA-EU/1/23/1782/002
Omjjara 150 mg film-coated tablets
A momelotinib product containing momelotinib dihydrochloride monohydrate, registered in Ireland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Momelotinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Momelotinib · ATC L01EJ04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of momelotinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Momelotinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$309.44
- FR France$0.16
The record
At a glance
HPRA (Ireland)- Active substance
- Momelotinib Dihydrochloride Monohydrate
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Ireland (IE)
- ATC code
- L01EJ04
- ATC class
- Momelotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1782/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Momelotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOmjjara 150 mgGlaxoSmithKline Trading Services
- SwitzerlandOmjjara 150 mg, FilmtablettenGlaxoSmithKline AG
- CzechiaOMJJARAGlaxoSmithKline Trading Services Limited, Dublin
- SpainOMJJARA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGlaxosmithkline Trading Services Limited
- FinlandOmjjaraGlaxosmithkline Trading Services Limited
- FranceOMJJARA 150 mg, comprimé pelliculéGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- IcelandOmjjaraGlaxoSmithKline Trading Services Limited
- NetherlandsOmjjara 150 mg, filmomhulde tablettenGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omjjara
- Liechtenstein · Omjjara
- Norway · Omjjara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e70573f5-c7fc-4792-85b6-82e303fa58aa GET /v1/drugs/e70573f5-c7fc-4792-85b6-82e303fa58aa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EJ04"
],
"strength": null,
"pa_number": "EU/1/23/1782/002",
"substances": [
"Momelotinib Dihydrochloride Monohydrate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "25/01/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about momelotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.